Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.32 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13685179 | 1.00 | BACE1 (0.43) | BACE1PLGKMT2AL3MBTL1FAP | |
| SCHEMBL13684965 | 1.00 | BACE1 (0.43) | BACE1PLGKMT2AL3MBTL1FAP | |
| SCHEMBL13685093 | 0.89 | BACE1 (0.51) | BACE1PLGREN | |
| SCHEMBL13685129 | 0.86 | BACE1 (0.36) | BACE1REN | |
| SCHEMBL13685011 | 0.86 | BACE1 (0.36) | BACE1REN | |
| SCHEMBL13686171 | 0.86 | BACE1 (0.36) | BACE1REN | |
| SCHEMBL13685100 | 0.86 | F2 (0.33) | BACE1PLG | |
| SCHEMBL8289304 | 0.84 | F2 (0.32) | BACE1PLGKMT2A | |
| SCHEMBL8034474 | 0.84 | F2 (0.32) | BACE1PLGKMT2A | |
| SCHEMBL8290545 | 0.84 | CTSD (0.33) | BACE1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | BACE1 392/4885PLG 359/4885KMT2A 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.